Metabolic Complications Using a Low- Versus High Concentration Citrate Solution for Regional Anticoagulation in Continuous Kidney Replacement Therapy: A Pragmatic Randomized Trial

Completed · Not applicable

Conditions studied: Acute Kidney Injury

In brief

This study is a pragmatic, randomized trial comparing two commercially available citrate solutions to determine their impact on metabolic complications in critically ill patients with acute kidney injury receiving continuous kidney replacement therapy with regional citrate anticoagulation.

Key facts

Study ID

NCT07751861

Run by

University Hospital, Antwerp

People needed

176

Starts

2023-10-01

Expected to finish

2025-04-01

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any adult patient admitted to the intensive care unit with acute kidney injury requiring continuous kidney replacement therapy

You may not qualify if…

• expected duration of continuous kidney replacement therapy less than 96 hours
• prior continuous kidney replacement therapy before inclusion
• a known hypersensitivity to citrate, acute liver failure or liver cirrhosis Child-Pugh C
• persistent severe hemodynamic shock with decreased lactate clearance
• a high likelihood of dying within the first 24h after initiation of CKRT
• preexisting severe electrolyte disorders before CKRT initiation not attributable to Acute kidney injury

Where it is running

• Antwerp University Hospital — Edegem, Antwerp, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.